SELLAS Life Sciences Group (NASDAQ:SLS) Stock Price Down 8.4% – Should You Sell?

Shares of SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) dropped 8.4% during trading on Tuesday . The company traded as low as $4.54 and last traded at $4.5810. Approximately 4,668,402 shares were traded during trading, a decline of 74% from the average daily volume of 18,296,564 shares. The stock had previously closed at $5.00.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of SELLAS Life Sciences Group in a research note on Wednesday, October 8th. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, SELLAS Life Sciences Group presently has a consensus rating of “Hold” and a consensus target price of $7.00.

SELLAS Life Sciences Group Stock Down 4.5%

The firm has a market capitalization of $549.82 million, a P/E ratio of -13.79 and a beta of 2.26. The company has a fifty day simple moving average of $2.18 and a 200 day simple moving average of $1.96.

SELLAS Life Sciences Group (NASDAQ:SLS) last issued its quarterly earnings results on Wednesday, November 12th. The company reported ($0.06) earnings per share for the quarter, beating the consensus estimate of ($0.08) by $0.02. As a group, equities analysts expect that SELLAS Life Sciences Group, Inc. will post -0.57 earnings per share for the current fiscal year.

Insider Transactions at SELLAS Life Sciences Group

In other news, Director Katherine Bach Kalin bought 63,400 shares of the company’s stock in a transaction dated Wednesday, November 19th. The shares were purchased at an average price of $1.59 per share, for a total transaction of $100,806.00. Following the completion of the purchase, the director owned 104,400 shares in the company, valued at approximately $165,996. This represents a 154.63% increase in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Company insiders own 1.40% of the company’s stock.

Institutional Investors Weigh In On SELLAS Life Sciences Group

Institutional investors and hedge funds have recently made changes to their positions in the company. Dagco Inc. purchased a new position in SELLAS Life Sciences Group in the 4th quarter worth approximately $2,177,000. Everhart Financial Group Inc. increased its holdings in shares of SELLAS Life Sciences Group by 40.8% in the 4th quarter. Everhart Financial Group Inc. now owns 466,216 shares of the company’s stock worth $1,758,000 after purchasing an additional 135,066 shares in the last quarter. Bank of America Corp DE raised its stake in shares of SELLAS Life Sciences Group by 21.9% in the third quarter. Bank of America Corp DE now owns 42,150 shares of the company’s stock worth $68,000 after purchasing an additional 7,571 shares during the last quarter. Anson Funds Management LP lifted its holdings in shares of SELLAS Life Sciences Group by 2,093.8% during the third quarter. Anson Funds Management LP now owns 6,032,938 shares of the company’s stock valued at $9,713,000 after purchasing an additional 5,757,938 shares in the last quarter. Finally, Equitable Holdings Inc. boosted its position in shares of SELLAS Life Sciences Group by 58.6% during the third quarter. Equitable Holdings Inc. now owns 27,060 shares of the company’s stock valued at $44,000 after buying an additional 10,000 shares during the last quarter. Institutional investors own 17.38% of the company’s stock.

SELLAS Life Sciences Group Company Profile

SELLAS Life Sciences Group, Inc is a clinical-stage biopharmaceutical company focused on the development of active cellular immunotherapies for cancer. Headquartered in Waltham, Massachusetts, SELLAS specializes in targeting the Wilms’ tumor 1 (WT1) antigen, a protein commonly overexpressed in a range of hematologic and solid tumors. Since its founding, the company has built a pipeline around the use of peptide-based vaccines designed to train the patient’s own immune system to recognize and attack WT1-positive cancer cells.

The company’s lead product candidate, galinpepimut-S (GPS), is an investigational multi-peptide vaccine directed against WT1.